Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -41.18% [1] - The company posted revenues of $8.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.14%, and down from $12.05 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Shares of Aquestive Therapeutics have declined approximately 21.6% since the beginning of the year, compared to a decline of -3.8% for the S&P 500 [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $11.87 million, and for the current fiscal year, it is -$0.65 on revenues of $49.55 million [7] - The estimate revisions trend for Aquestive Therapeutics is currently unfavorable, which may change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]